bluebird bio, Inc. (BLUE) Stake Maintained by Woodstock Corp
Woodstock Corp maintained its position in bluebird bio, Inc. (NASDAQ:BLUE) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 9,090 shares of the biotechnology company’s stock at the end of the second quarter. Woodstock Corp’s holdings in bluebird bio were worth $955,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Martingale Asset Management L P raised its position in bluebird bio by 0.6% in the first quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 100 shares in the last quarter. Legal & General Group Plc raised its position in shares of bluebird bio by 2.6% in the first quarter. Legal & General Group Plc now owns 13,944 shares of the biotechnology company’s stock worth $1,272,000 after buying an additional 357 shares during the period. First Mercantile Trust Co. raised its position in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the period. Dimensional Fund Advisors LP raised its position in shares of bluebird bio by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 68,220 shares of the biotechnology company’s stock worth $4,210,000 after buying an additional 540 shares during the period. Finally, Bank of Montreal Can raised its position in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the period.
Shares of bluebird bio, Inc. (BLUE) opened at 98.65 on Tuesday. The company’s market capitalization is $4.49 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $123.75. The firm’s 50-day moving average price is $102.86 and its 200 day moving average price is $88.98.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. During the same quarter last year, the business posted ($1.59) EPS. The company’s quarterly revenue was up 977.4% compared to the same quarter last year. Analysts anticipate that bluebird bio, Inc. will post ($6.69) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Stake Maintained by Woodstock Corp” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/08/woodstock-corp-has-955000-position-in-bluebird-bio-inc-blue-updated-updated-updated.html.
A number of brokerages recently issued reports on BLUE. Morgan Stanley boosted their target price on shares of bluebird bio from $103.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Monday. BMO Capital Markets reaffirmed a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research report on Friday. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Sanford C. Bernstein started coverage on shares of bluebird bio in a report on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “sell” rating and issued a $39.00 price target on shares of bluebird bio in a report on Monday, July 24th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company’s stock. bluebird bio currently has an average rating of “Hold” and an average target price of $100.66.
In other news, insider Nick Leschly sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 27th. The stock was sold at an average price of $108.05, for a total value of $2,701,250.00. Following the completion of the transaction, the insider now owns 360,656 shares in the company, valued at approximately $38,968,880.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel Lynch sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $80.00, for a total value of $160,000.00. Following the transaction, the director now directly owns 3,400 shares of the company’s stock, valued at approximately $272,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 77,106 shares of company stock valued at $8,018,895. Company insiders own 3.90% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.